Table 2 Combination of GC-marker immunoreactivity in the series of FL
| Â | Triple-positive N.cases (%) | Double-positive N.cases (%) | Single-positive N.cases (%) | ||
|---|---|---|---|---|---|
Groups (N.cases) | HGAL/BCL6/CD10 | HGAL/BCL6 | HGAL/CD10 | BCL6 | HGAL |
In situ FL (6) | 3 (50%) | - | 3 (50%) | - | - |
Nodal FL (61) | 53 (87.1%) | 4 (6.5%) | 2 (3.2%) | 2 (3.2%) | - |
FL+LBCL (10) | 8 (80%) | 1 (10%) | - | - | 1 (10%) |
CFL (5) | 5 (100%) | - | - | - | - |
Total (82) | 69 (84.2%) | 5 (6.1%) | 5 (6.1%) | 2 (2.4%) | 1 (1.2%) |